Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: life extension

Summary: A team of scientists at Tongji University just announced a breakthrough in regenerating human lungs using stem cells, improving lung function in patients. [This article first appeared on the website LongevityFacts. Author: Brady Hartman. ]

A team of researchers from Tongji University in China announced what they say is a breakthrough in treating lung diseases by regenerating tissue using stem cell transplantation.

In a pilot clinical trial, the treatment proved effective at repairing the lung tissue of two patients suffering from lung diseases, who showed improvements in both symptoms and on CT scans, say the researchers. Zuo Wei is a Tongji University professor who led the research team and says.

Read more

Summary: A research team at UCSD discovered a key enzyme that plays a role in burning calories during both obesity and dieting and sabotages weight loss. Moreover, these scientists may have just found an existing drug that counteracts this enzyme. [This article first appeared on the website LongevityFacts.com. Author: Brady Hartman. ]

Ever wonder why dieting often leads to a plateau in weight loss? It happens because the body is trying to maintain a steady weight by regulating the expenditure of energy. How this happens has remained a mystery until now.

In a paper published on February 8 in the journal Cell, a team of researchers at the University of California San Diego (UCSD) School of Medicine led by Alan Saltiel, Ph.D. has identified a key enzyme that sabotages weight loss efforts during dieting. Dr. Saltiel is the director of UCSD’s Institute for Diabetes and Metabolic Health, and says.

Read more

The AHA names evolocumab — a new PCSK9 inhibitor — as one of the top 10 heart disease and stroke advances of 2017 in its annual list published on February 8, 2018. However, this novel cholesterol-lowering drug carries a big price tag.

Summary: The AHA names the PCSK9 inhibitor evolocumab as one of the top 10 heart disease and stroke advances of 2017 in its annual list published on February 8. However, this novel cholesterol-lowering drug carries a big price tag. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

The AHA named the cholesterol-lowering drug evolocumab in its annual top 10 lists of major advances in heart disease and stroke research, published on February 8. Evolocumab belongs to a class of cholesterol-lowering drugs called PCSK9 inhibitors and is injectable drug marketed by Amgen under the brand name Repatha. The two-year FOURIER study reported that evolocumab reduced high cholesterol levels and had few adverse effects.

The FOURIER study, published in the New England Journal of Medicine, found that evolocumab can significantly reduce heart attacks and strokes among high-risk patients. The study included more than 27,000 patients who were randomized into taking evolocumab or a placebo, and showed that the new drug has a clear benefit over statins in reducing LDL, the bad cholesterol in patients. FOURIER showed that the new medication cut the risk of having a heart attack, stroke or other cardiovascular events by 20% when added to intensive statin therapy. The study was paid for by Amgen and reported that evolocumab lowered LDL by about 60%, to a median of 30 mg/dL.

Read more

In a first for medical science, scientists in the UK have successfully created functioning human kidney tissue that produces urine.

Summary: In a first for medical science, researchers in the UK have successfully created functioning human kidney tissue that produces urine. [This article first appeared on the website LongevityFacts. Author: Brady Hartman. ]

In a first for medical science, researchers have successfully created human kidney tissue within a living organism which can produce urine.

The study led by professor Sue Kimber and professor Adrian Woolf from the University of Manchester in the UK marks a significant milestone in the development of kidney disease treatments. The scientists published their results on February 8 in the journal Stem Cell Reports.

Read more

Researchers just reported promising rapamycin clinical trial results in the first of its kind test of the drug’s safety and anti-aging effects on healthy Senior adults. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

A rapamycin clinical trial using healthy adults recently completed and reported the drug to be safe over the short-term when used for anti-aging purposes.

This clinical trial of rapamycin was one of the first testing the compound’s safety as an anti-aging drug in healthy Seniors. The clinical trial consisted of 25 healthy older adults 70–95 years between the ages of 70 to 95. The study participants took either a placebo or 1mg rapamycin daily for eight weeks. The main finding of the study was that the drug was safe, without significant side effects. The researchers published their results on February 3 in the journal Experimental Gerontology and concluded.

Read more

A Japanese scientist regrows hair follicles at record rate using a special ingredient – this novel technique could revolutionize the treatment of baldness. [This article first appeared on the website LongevityFacts.com. Author: Brady Hartman. ]

While scientists aim to lengthen our lifespans, at least they can lengthen our locks.

Or even grow a full head of hair on a bald pate, in the near future.

Read more

A scientist gets to the roots of hair loss in a study published at the end of January, saying baldness is due to metabolic changes and free radical damage – and suggests ways to solve the problem. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

Why We Grow Bald

Scientists have identified at least nine mechanisms that underly the aging process, the so-called hallmarks of aging. While there are many factors that contribute to baldness, including hormonal changes, two of these hallmarks have been implicated in age-related hair loss in women in a study published in late January of this year.

Read more

February 21st Dr. Oliver Medvedik is hosting a special AI vs Aging Livestream here on our Facebook page. Anastasia Georgievskaya, Alex Zhavoronkov, and guests will be taking part in this special panel focusing on AI in aging research.

Ask your questions about AI in research on the thread here and we will try to include them in the show.

Read more

So will we ever be able to do this or is this just a pipe dream? Plenty has been written about the future and what we may be able to do one day, but not much attention gets paid to the hurdles we have yet to overcome. Forget all the techno-babble, philosophy, and transhumanism – how close is this brave new world to our present time?

“Any way you look at it, all the information that a person accumulates in a lifetime is just a drop in a bucket.”

Taken from 1995’s Ghost in the Shell, this sentence perfectly sums up the complexity and ambiguity of the human mind and the brain. Despite enormous advances, our ignorance on what lies within our cranium remains vast and sometimes unyielding. Those drops, and their relation to the bucket, are profoundly enigmatic.

We understand how different parts of the brain communicate and often what they specialize in, but what exactly is a “thought” made of? Where, amongst the 86 billion neurons in our brain, do they come from, and where do they go? What, scientifically speaking, is consciousness – is it a single entity or the sum of trillions of permutations? Is it the addition or average of all those firing neurons?

Read more

Summary: Clues to the naked mole rat’s remarkable cancer-fighting abilities have been uncovered by researchers at the University of Rochester in a new study. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

With their wrinkled, hairless bodies, naked mole rats won’t be winning any beauty contests.

However, they do win longevity contests.

Read more